Abstract
Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.
| Original language | English |
|---|---|
| Pages (from-to) | 663-670 |
| Number of pages | 8 |
| Journal | Journal of Nephrology |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Oct 2017 |
Cite this
}
Circulating markers of bone turnover. / Vervloet, Marc G.; Brandenburg, Vincent; on behalf of CKD-MBD working group of ERA-EDTA.
In: Journal of Nephrology, Vol. 30, No. 5, 01.10.2017, p. 663-670.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Circulating markers of bone turnover
AU - Vervloet, Marc G.
AU - Brandenburg, Vincent
AU - Bover, Jordi
AU - Brandenburg, Vincent
AU - Covic, Adrian
AU - Cozzolino, Mario
AU - Evenepoel, Pieter
AU - Goldsmith, David
AU - Massy, Ziad
AU - Mazzaferro, Sandro
AU - Ūrena-Torres, Pablo
AU - Vervloet, Marc G.
AU - on behalf of CKD-MBD working group of ERA-EDTA
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.
AB - Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.
KW - Biomarkers
KW - Bone turnover
KW - Chronic kidney disease
KW - CKD-MBD
UR - http://www.scopus.com/inward/record.url?scp=85030528620&partnerID=8YFLogxK
U2 - 10.1007/s40620-017-0408-8
DO - 10.1007/s40620-017-0408-8
M3 - Review article
VL - 30
SP - 663
EP - 670
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 5
ER -